|
A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140). |
|
|
Research Funding - Aduro Biotech (Inst); Bayer (Inst); Morphotek (Inst); Roche TCRC (Inst) |
Patents, Royalties, Other Intellectual Property - Royalties for MPF assay from Morphotek (approximately $700/year) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Bayer; Bristol-Myers Squibb; Celgene; Clavis Pharma; Merck |
Research Funding - Bayer; Bristol-Myers Squibb; Celgene; Merck; Novartis |
Travel, Accommodations, Expenses - Abbvie; Bayer; Bristol-Myers Squibb; Celgene; Merck |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Aduro Biotech; AstraZeneca; Bayer; Celgene; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; MedImmune; Merck; Plexxikon; Verastem |
Research Funding - AB Science; Aduro Biotech; Astellas Pharma; AstraZeneca; Bayer; Celgene; GlaxoSmithKline; Incyte; MedImmune; Merck; Verastem |
Expert Testimony - Aduro Biotech |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |